Drug Search Results
More Filters [+]

CJ-50300

Alternative Names: cj-50300, cj50300, cj 50300
Latest Update: 2013-12-06
Latest Update Note: Clinical Trial Update

Product Description

cell-culture derived smallpox vaccine; infects MRC-5 cells (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00336635)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Seoul National University Hospital
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CJ-50300

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Smallpox

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CJ_SPX_303

P3

Completed

Smallpox

2011-07-01

CJ_SPX_302

P3

Completed

Smallpox

2010-12-01

CJ_SPX_301

P3

Completed

Smallpox

2008-06-01

Recent News Events

Date

Type

Title